Download PDF
CC BY 4.0 · Indian J Med Paediatr Oncol 2024; 45(01): 044-051
DOI: 10.1055/s-0043-1771403
Original Article

Unveiling the Molecular Mechanisms Behind the Devastating Impact of the ALK Protein on Pediatric Cancers: Insights into Deleterious SNPs through In Silico Predictions, Molecular Docking, and Dynamics Studies

Abdulhadi Almazroea
1   Associate Professor of General Pediatrics, Medical College, Taibah University, Saudi Arabia
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Introduction Pediatric cancers present significant challenges in terms of diagnosis and treatment, and the anaplastic lymphoma kinase (ALK) protein has emerged as a crucial molecular target in these malignancies. ALK, a receptor tyrosine kinase, plays a vital role in normal cellular processes, but genetic alterations and aberrant activation of the ALK gene have been implicated in various pediatric cancer types. While genetic alterations have been well studied, the precise molecular mechanisms underlying the pathogenicity of the ALK protein in pediatric cancers remain poorly understood.

Objective In this study, the primary objective is to uncover the molecular mechanisms associated with the effects of deleterious single-nucleotide polymorphisms (SNPs) on the structure and functionality of the ALK protein.

Material and Methods Several known point mutations of the ALK protein were taken for the in silico predictions such as PolyPhen-2, SIFT, PANTHER, PredictSNP, etc., residue conservation analysis using Consurf server, molecular docking (AutoDock), and molecular dynamics simulation studies (GROMACS).

Results The computation predictions found that the studied variants are deleterious in different tools. The residue conservation analysis reveals all the variants are located in highly conserved regions. The molecular docking study of wild-type and mutant structures with the crizotinib drug molecule found the variants were modulating the binding cavity and had a strong impact on the binding affinity. The binding energy of the wild-type is –5.896 kcal/mol, whereas the mutants have –9.988 kcal/mol. The specific amino acid Ala1200 of wild-type was found to interact with crizotinib, and Asp1203 residue was found to interact predominantly in the mutant structures.

Conclusion The simulation study differentiates the variants in terms of structural stability and residue fluctuation. Among the studied variants, R1275Q, F1245V, and F1174L had strong deleterious effects, structural changes, and pathogenicity based on the in silico predictions. By elucidating the functional consequences of deleterious mutations within the ALK gene, this research may uncover novel therapeutic targets and personalized medicine approaches for the management of pediatric cancers. Ultimately, gaining insights into the molecular mechanisms of the ALK protein's role in driving response and resistance will contribute to improving patient outcomes and advancing our understanding of this complex disease.

Keywords

ALK - pediatric cancer - SNP - molecular docking - molecular dynamics simulation

Financial Support

None.


Supplementary Material



Publication History

Article published online:
26 September 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Bresler SC, Weiser DA, Huwe PJ. et al. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. Cancer Cell 2014; 26 (05) 682-694
    CrossrefPubMedSearch in Google Scholar
  • 2 Roskoski Jr R. Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition. Pharmacol Res 2013; 68 (01) 68-94
    CrossrefPubMedSearch in Google Scholar
  • 3 Gridelli C, Peters S, Sgambato A, Casaluce F, Adjei AA, Ciardiello F. ALK inhibitors in the treatment of advanced NSCLC. Cancer Treat Rev 2014; 40 (02) 300-306
    CrossrefPubMedSearch in Google Scholar
  • 4 Mossé YP. Anaplastic lymphoma kinase as a cancer target in pediatric malignancies. Clin Cancer Res 2016; 22 (03) 546-552
    CrossrefPubMedSearch in Google Scholar
  • 5 Roskoski Jr R. The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders. Expert Opin Drug Discov 2013; 8 (09) 1165-1179
    CrossrefPubMedSearch in Google Scholar
  • 6 Schönherr C, Ruuth K, Yamazaki Y. et al. Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684. Biochem J 2011; 440 (03) 405-413
    CrossrefPubMedSearch in Google Scholar
  • 7 Infarinato NR, Park JH, Krytska K. et al. The ALK/ROS1 inhibitor PF-06463922 overcomes primary resistance to crizotinib in ALK-driven neuroblastoma. Cancer Discov 2016; 6 (01) 96-107
    CrossrefPubMedSearch in Google Scholar
  • 8 Desai A, Lovly CM. Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review. Transl Lung Cancer Res 2023; 12 (03) 615-628
    CrossrefPubMedSearch in Google Scholar
  • 9 Ando K, Manabe R, Kishino Y. et al. Comparative efficacy of ALK inhibitors for treatment-naïve ALK-positive advanced non-small cell lung cancer with central nervous system metastasis: a network meta-analysis. Int J Mol Sci 2023; 24 (03) 2242
    CrossrefPubMedSearch in Google Scholar
  • 10 Karachaliou N, Santarpia M, Gonzalez Cao M. et al. Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer. Expert Opin Investig Drugs 2017; 26 (06) 713-722
    CrossrefPubMedSearch in Google Scholar
  • 11 Katayama R, Lovly CM, Shaw AT. Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine. Clin Cancer Res 2015; 21 (10) 2227-2235
    CrossrefPubMedSearch in Google Scholar
  • 12 Loganathan L, Kuriakose BB, Mushfiq S, Muthusamy K. Mechanistic insights on nsSNPs on binding site of renin and cytochrome P450 proteins: a computational perceptual study for pharmacogenomics evaluation. J Cell Biochem 2021; 122 (10) 1460-1474
    CrossrefPubMedSearch in Google Scholar
  • 13 George Priya Doss C, Nagasundaram N, Chakraborty C, Chen L, Zhu H. Extrapolating the effect of deleterious nsSNPs in the binding adaptability of flavopiridol with CDK7 protein: a molecular dynamics approach. Hum Genomics 2013; 7 (01) 10
    CrossrefPubMedSearch in Google Scholar
  • 14 Rajasekaran R, Sudandiradoss C, Doss CGP, Sethumadhavan R. Identification and in silico analysis of functional SNPs of the BRCA1 gene. Genomics 2007; 90 (04) 447-452
    CrossrefPubMedSearch in Google Scholar
  • 15 Mi H, Muruganujan A, Thomas PD. PANTHER in 2013: modeling the evolution of gene function, and other gene attributes, in the context of phylogenetic trees. Nucleic Acids Res 2013; 41 (Database issue, D1): D377-D386
    CrossrefPubMedSearch in Google Scholar
  • 16 Johnson AD, Handsaker RE, Pulit SL, Nizzari MM, O'Donnell CJ, de Bakker PI. SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics 2008; 24 (24) 2938-2939
    CrossrefPubMedSearch in Google Scholar
  • 17 Landau M, Mayrose I, Rosenberg Y. et al. ConSurf 2005: the projection of evolutionary conservation scores of residues on protein structures. Nucleic Acids Res 2005; 33 (Web Server issue): W299-302
    CrossrefPubMedSearch in Google Scholar
  • 18 Ashkenazy H, Abadi S, Martz E. et al. ConSurf 2016: an improved methodology to estimate and visualize evolutionary conservation in macromolecules. Nucleic Acids Res 2016; 44 (W1): W344-50
    CrossrefPubMedSearch in Google Scholar
  • 19 Carlus SJ, Almuzaini IS, Karthikeyan M. et al. Next-generation sequencing identifies a homozygous mutation in ACADVL associated with pediatric familial dilated cardiomyopathy. Eur Rev Med Pharmacol Sci 2019; 23 (04) 1710-1721
    PubMedSearch in Google Scholar
  • 20 Ogrizek M, Turk S, Lešnik S. et al. Molecular dynamics to enhance structure-based virtual screening on cathepsin B. J Comput Aided Mol Des 2015; 29 (08) 707-712
    CrossrefPubMedSearch in Google Scholar
  • 21 Choudhry H, Alzahrani FA, Hassan MA. et al. Zika virus targeting by screening inhibitors against NS2B/NS3 protease. BioMed Res Int 2019; 2019: 3947245
    CrossrefPubMedSearch in Google Scholar
  • 22 Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 2010; 31 (02) 455-461
    CrossrefPubMedSearch in Google Scholar
  • 23 Release S. 2023–2: Maestro. New York, NY: Schrödinger, LLC; 2023
    Search in Google Scholar
  • 24 Loganathan L, Muthusamy K. Investigation of drug interaction potentials and binding modes on direct renin inhibitors. A computational modeling studies. Lett Drug Des Discov 2019; 16 (08) 919-938
    CrossrefSearch in Google Scholar
  • 25 Loganathan L, Natarajan K, Muthusamy K. Computational study on cross-talking cancer signalling mechanism of ring finger protein 146, AXIN and Tankyrase protein complex. J Biomol Struct Dyn 2020; 38 (17) 5173-5185
    CrossrefPubMedSearch in Google Scholar
  • 26 Jayaraman M, Loganathan L, Muthusamy K. et al. Virtual screening assisted discovery of novel natural products to inhibit the catalytic mechanism of Mycobacterium tuberculosis InhA. J Mol Liq 2021; 335: 116204
    CrossrefSearch in Google Scholar
  • 27 Loganathan L, Gopinath K, Sankaranarayanan VM. et al. Computational and pharmacogenomic insights on hypertension treatment: rational drug design and optimization strategies. Curr Drug Targets 2020; 21 (01) 18-33
    CrossrefPubMedSearch in Google Scholar
  • 28 Loganathan L, Al-Haidose A, Ganesh Kumar A. et al. An in silico analysis of the impact of POLE mutations on cladribine docking. Eur Rev Med Pharmacol Sci 2022; 26 (20) 7580-7593
    PubMedSearch in Google Scholar